Allergic Conjunctivitis Differential Diagnosis: A Comprehensive Guide for Clinicians

Allergic conjunctivitis is a highly common ocular condition that eye care professionals frequently encounter. It is estimated to affect up to 40% of the population. Despite its widespread occurrence, many individuals suffering from allergic conjunctivitis do not seek medical attention, leading to a significant rate of underdiagnosis and consequently, undertreatment. The hallmark symptom of this condition is itching, and typical management strategies involve topical antihistamines and mast cell stabilizers.

This article aims to provide clinicians with an in-depth understanding of allergic conjunctivitis, covering its clinical presentation, the underlying immunological mechanisms, and various therapeutic approaches. Through detailed discussion and the presentation of current pharmacological insights, this resource will equip healthcare providers with the necessary knowledge to optimize patient care and improve outcomes in the management of allergic conjunctivitis. Furthermore, this article will emphasize the importance of an interprofessional team approach, highlighting the collaborative roles of primary care physicians, optometrists, and ophthalmologists in the comprehensive care of patients with allergic conjunctivitis.

Objectives:

• To distinguish between the different subtypes of allergic conjunctivitis, including seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), and atopic keratoconjunctivitis (AKC).
• To effectively screen patients for allergic conjunctivitis risk factors, considering family history, environmental exposures, and atopic predispositions.
• To implement both pharmacological and non-pharmacological interventions for managing allergic conjunctivitis, tailoring treatment plans to meet the unique needs of each patient.
• To communicate effectively with patients about their condition, available treatment options, and potential complications, ensuring thorough patient understanding and treatment adherence.

Introduction

Allergic conjunctivitis is a prevalent, often underestimated, and generally benign condition. Its increasing prevalence over the last decade has solidified its position as one of the most frequently seen conditions in clinical practice. The development of allergic conjunctivitis is multifactorial, influenced by genetic predisposition, inflammatory processes, air pollution, atopy, exposure to pollen, and contact with pets. It’s important to note that allergic conjunctivitis can progress to keratoconjunctivitis and potentially lead to visual impairment in some cases. While it rarely poses a direct threat to vision, allergic conjunctivitis can significantly diminish a patient’s quality of life due to persistent and uncomfortable symptoms.

Simple allergic conjunctivitis is broadly categorized into three subtypes: acute, seasonal, and perennial. Furthermore, the spectrum of allergic conjunctivitis encompasses a wider range of conditions including seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), and atopic keratoconjunctivitis (AKC).

Although VKC and AKC exhibit distinct clinical and pathophysiological characteristics compared to SAC and PAC, certain consistent markers remain across all subtypes of allergic conjunctivitis.

Giant papillary conjunctivitis (GPC) is another condition considered within the ocular allergy spectrum. GPC typically arises from contact lens wear or microtrauma associated with ocular prostheses. Treatment strategies and some aspects of the pathophysiology are notably similar between atopic conjunctivitis (VKC, AKC) and giant papillary conjunctivitis. Therefore, all these conditions are classified under the umbrella of ocular allergies. Initial treatment approaches may be similar for these conditions, but it is crucial to recognize that outcomes and complication rates can vary significantly among them.

Etiology

Simple Allergic Conjunctivitis

In the majority of cases, allergic conjunctivitis is caused by direct exposure of the ocular surface to allergens.

Seasonal Allergic Conjunctivitis (SAC)

SAC, commonly known as “hay fever eyes,” typically worsens during the spring and summer seasons. The most frequent culprits are tree and grass pollens, although the specific allergens responsible can vary depending on geographic location and the local flora.

Perennial Allergic Conjunctivitis (PAC)

PAC can occur year-round but is often more pronounced in the autumn. This subtype is primarily triggered by indoor allergens such as house dust mites, animal dander, and fungal spores. Compared to SAC, perennial allergic conjunctivitis is generally less common and tends to be milder in its presentation.

Vernal Keratoconjunctivitis (VKC)

The precise etiology of VKC remains incompletely understood. It is believed to be a complex condition resulting from an interplay of climatic factors and allergen exposure. Both Immunoglobulin E (IgE)-mediated and cell-mediated immune mechanisms are thought to play critical roles in the pathogenesis of VKC. VKC is further classified into three clinical forms based on its predominant site of presentation:

• Palpebral VKC: This form primarily affects the upper tarsal conjunctiva, the inner lining of the upper eyelid. Palpebral VKC often leads to significant corneal involvement due to the close contact between the inflamed tarsal conjunctiva and the corneal epithelium.

• Limbal VKC: Limbal VKC is a distinct subtype that predominantly affects the limbus, the border between the cornea and sclera. This form is more commonly seen in individuals of Black and Asian descent.

• Mixed VKC: As the name suggests, mixed VKC presents with features of both palpebral and limbal disease. It exhibits manifestations involving both the upper tarsal conjunctiva and the limbal area.

Atopic Keratoconjunctivitis (AKC)

The exact cause of atopic keratoconjunctivitis is not fully elucidated. However, it is generally accepted to be a multifactorial condition arising from a combination of allergen exposure, atopic dermatitis (which is present in over 90% of cases), and genetic predisposition.

Giant Papillary Conjunctivitis (GPC)

The allergic response in giant papillary conjunctivitis is typically triggered by ocular foreign bodies. These foreign bodies, such as contact lenses, ocular prostheses, cyanoacrylate glue, and sutures, can act in two ways: they may harbor allergens on their surface, or they can cause microtrauma to ocular tissues, facilitating the infiltration of allergens and subsequent immune response.

Epidemiology

Simple Allergic Conjunctivitis

Simple allergic conjunctivitis is frequently underdiagnosed, as many sufferers do not seek medical attention for their symptoms. This under-appreciation makes it challenging to determine the precise prevalence. However, estimates suggest that simple allergic conjunctivitis affects approximately 10% to 30% of the general population. The onset is most common in individuals under 20 years of age, with prevalence tending to decrease in older age groups. While allergic conjunctivitis can occur in isolation, it is frequently associated with other atopic conditions, such as allergic rhinitis, atopic dermatitis, and asthma.

Vernal Keratoconjunctivitis (VKC)

VKC shows a marked predilection for males, with a male-to-female ratio ranging from 2:1 to 3:1. It predominantly affects children and young adolescents, with most cases occurring in patients between 5 and 10 years old. Often, these patients have a personal or family history of atopy or asthma. Approximately 95% of patients experience spontaneous remission by late adolescence, while the remaining percentage may progress to develop atopic keratoconjunctivitis later in life.

VKC is more prevalent in warm, dry climates, such as the Middle East, sub-Saharan Africa, and the Mediterranean region, and is less commonly seen in temperate climates. In temperate regions, a high proportion (around 90%) of VKC patients also present with atopy, asthma, and eczema, and approximately two-thirds have a documented history of atopy.

The peak onset of VKC symptoms typically occurs in late spring and summer, although some patients may experience mild perennial symptoms that persist throughout the year.

Atopic Keratoconjunctivitis (AKC)

AKC typically does not manifest before adolescence and reaches its peak prevalence in individuals between 30 and 50 years of age. It is a relatively rare, bilateral disease that is more commonly observed in individuals with a pre-existing history of atopic dermatitis and asthma. In fact, most cases of AKC occur in patients with atopic dermatitis.

Similar to VKC, AKC shows a male predominance, with a male-to-female ratio between 2:1 and 3:1. Approximately 5% of AKC patients have a prior history of childhood VKC. AKC is a chronic condition with a low likelihood of spontaneous resolution and can lead to significant visual morbidity if not properly managed.

AKC tends to be a perennial condition, often worsening during the winter months. Individuals with AKC exhibit sensitivity to a broad spectrum of airborne environmental pathogens and irritants.

Giant Papillary Conjunctivitis (GPC)

GPC is frequently observed in teenagers and young adults, likely due to its strong association with contact lens wear, which is more common in these age groups. It is most prevalent among users of soft contact lenses, affecting approximately 5% of this population. GPC typically develops 1 to 2 years after initiating soft contact lens use, although the onset can vary considerably depending on the type of ocular foreign body involved.

GPC can be triggered by a variety of stimuli that affect the tarsal conjunctiva. It is also frequently referred to as contact lens-induced papillary conjunctivitis (CLPC). Protein deposits and cellular debris can accumulate on contact lenses, ocular prostheses, sutures, and scleral buckles, acting as irritants and triggering the inflammatory response. Additionally, irregular corneal surfaces or filtering blebs can also contribute to the development of GPC.

The phenomenon known as mucus fishing syndrome, characterized by a chronic papillary reaction resulting from repeated manual removal of mucus, can also lead to GPC. Furthermore, GPC can coexist with other forms of allergic conjunctivitis such as AKC and VKC.

Pathophysiology

Simple allergic conjunctivitis, including acute, seasonal, and perennial forms, is primarily mediated by an immunoglobulin E (IgE)-mediated hypersensitivity reaction (Type I). This reaction is initiated when an allergen directly contacts the ocular surface. This interaction triggers the degranulation of mast cells, leading to the release of various inflammatory mediators such as histamine, prostaglandins, and leukotrienes.

The precise pathophysiological mechanisms underlying VKC are complex and not fully understood. However, current evidence suggests that it involves both IgE-mediated hypersensitivity (Type I) and T-cell involvement, indicating a mixed Type I and Type IV hypersensitivity reaction.

Atopic keratoconjunctivitis (AKC) appears to be a result of both delayed-type (Type IV) and immediate (Type I) hypersensitivity reactions to ocular allergen exposure. This dual mechanism contributes to the chronic and severe nature of AKC.

Giant papillary conjunctivitis (GPC) develops secondary to direct mechanical irritation or injury to the conjunctiva. This mechanical insult triggers an immune response involving both Type I and Type IV hypersensitivity reactions. In GPC, the foreign object, such as a contact lens, may become coated with various allergens or cause epithelial tissue damage. This damage facilitates deeper allergen penetration and exposure to immune cells, initiating and perpetuating the immunological response.

Histopathology

In Vernal Keratoconjunctivitis (VKC), histopathological examination reveals a characteristic accumulation of eosinophils, mast cells, and fibroblast proliferation within the conjunctival tissue. Biochemical stains will demonstrate the presence of inflammatory enzymes, including proteases, chymases, and tryptases. The substantia propria, the connective tissue layer of the conjunctiva, is thickened due to collagen deposition. Furthermore, T and B lymphocytes, which are responsible for the production of IgE and IgG antibodies, are also present in the affected tissue. This overall histopathological picture is consistent with a combination of both type I and type IV hypersensitivity reactions.

Atopic Keratoconjunctivitis (AKC) is characterized by a less pronounced increase in eosinophils and mast cells compared to VKC. However, tear fluid analysis in AKC patients often reveals elevated levels of IgE. These findings suggest that a Type I hypersensitivity reaction plays a significant role in AKC, although Type IV mechanisms are also implicated.

Giant Papillary Conjunctivitis (GPC) histopathology shows infiltration of various white blood cells, including plasma cells, mast cells, lymphocytes, basophils, and eosinophils into the conjunctival tissue. Elevated levels of IgE can also be detected in the tears of individuals with GPC, further supporting the involvement of allergic mechanisms in its pathogenesis.

History and Physical Examination

Allergic conjunctivitis frequently occurs in conjunction with systemic seasonal allergy symptoms, particularly in individuals with known allergies or a history of atopy. Consequently, recurrent episodes are a common feature. When evaluating a patient suspected of having allergic conjunctivitis, healthcare providers should obtain a detailed history regarding personal allergies, atopy, and any previous episodes of similar symptoms. It is important to inquire about the symptoms experienced during the current episode as well as in past occurrences. The most commonly reported symptoms across all subtypes of allergic conjunctivitis are itchiness and diffuse bulbar and tarsal conjunctival injection (redness). However, other aspects of the patient’s history and physical examination findings can vary depending on the specific subtype of allergic conjunctivitis.

Simple Allergic Conjunctivitis

The typical discharge in simple allergic conjunctivitis is clear and watery. It usually affects both eyes (bilateral) and may present with minimal crusting upon waking in the mornings. Pain and decreased visual acuity are not common symptoms of simple allergic conjunctivitis. If these symptoms are present, it should raise suspicion for an alternative diagnosis and prompt further investigation. Eyelid edema (swelling) and chemosis (swelling of the conjunctiva) are common signs and can be quite pronounced.

Patients with simple allergic conjunctivitis often experience transient acute or subacute episodes of eye redness, watery discharge, and intense itching. These episodes are frequently associated with systemic allergy symptoms such as sneezing, nasal discharge (rhinorrhea), and other manifestations of allergic rhinitis. Conjunctival hyperemia (redness) with mild papillary reaction, variable chemosis, and eyelid edema are characteristic findings on physical examination.

Vernal Keratoconjunctivitis (VKC)

Symptoms of VKC are typically most severe during the spring season. These symptoms can include thick, mucus discharge, eye pain, excessive tearing (lacrimation), photophobia (light sensitivity), and blurred vision. Patients often describe a foreign body sensation in the eye and may exhibit increased blinking. Upon examination, corneal ulcers and infiltrates on the conjunctiva can occasionally be detected. A hallmark sign of VKC is the presence of giant papillae on the tarsal conjunctiva, which are almost universally observed during clinical examination.

Palpebral Vernal Keratoconjunctivitis

In the early stages of palpebral VKC, examination reveals mild conjunctival hyperemia and diffuse velvety hypertrophy (thickening) of the superior tarsal plate. Macropapillae, which are smaller than 1 mm in size, appear as flat-topped lesions with a polygonal or “cobblestone-like” appearance on the tarsal conjunctiva. These macropapillae can be focal or diffusely distributed. In more severe cases, whitish inflammatory infiltrates may be observed, indicating more intense disease activity.

Giant papillae, which are larger than 1 mm, are formed by the amalgamation of smaller lesions when the dividing septa rupture. Mucus deposits are often seen between these giant papillae. Reduced conjunctival injection and decreased mucus production are characteristic of periods of decreased disease activity or remission.

Limbal Vernal Keratoconjunctivitis

The limbal form of VKC is characterized by gelatinous conjunctival papillae, which are typically located at the limbal region of the eye (the junction between the cornea and sclera). Another distinctive finding is the presence of Horner-Trantas dots. These are transient, whitish-yellow cellular collections located apically on the limbus, representing accumulations of eosinophils and epithelial cells.

Limbal VKC tends to be more severe in tropical climates compared to temperate regions.

Atopic Keratoconjunctivitis (AKC)

The symptoms of AKC are typically perennial and include persistent eye pain, blurry vision, photophobia, and a foreign body sensation. Examination findings can be similar to those seen in simple allergic conjunctivitis, such as conjunctival hyperemia and chemosis. However, AKC is distinguished by the presence of chronic inflammatory changes to the ocular surface, which may include corneal scarring and neovascularization (abnormal blood vessel growth). Changes to the eyelids, particularly the lower lid, and the peri-orbital skin are also characteristic and can range from mild atopy to lichenification (thickening and hardening of the skin).

In comparison to VKC, the symptoms of AKC are generally less severe in intensity but are persistent and chronic. The skin changes in AKC are typically more pronounced and include eczema, erythema (redness), dryness, and scaly skin, often associated with thickening. Disruption of epidermal integrity leads to fissures, excoriations (scratches), cracks, and intense itching of the eyelids and periocular skin.

Other associated signs in AKC can include chronic staphylococcal blepharitis (eyelid inflammation), madarosis (loss of eyelashes), keratinization of the lid margin, Hertoghe sign (thinning or absence of the lateral portion of the eyebrows), and Dennie-Morgan folds (skin folds on the lower eyelids due to chronic rubbing and edema). Facial skin may exhibit folds, ectropion (outward turning of the eyelid), and epiphora (excessive tearing). Patients may also develop ptosis (drooping of the upper eyelid). In AKC, inferior palpebral conjunctival involvement is more common than the superior involvement typically seen in VKC. The discharge in AKC is usually watery, compared to the stringy mucoid discharge more characteristic of VKC.

Hyperemia, inflammation, and chemosis may be present during active acute exacerbations of AKC. The papillae in AKC tend to be smaller than those seen in VKC, although macropapillae can also develop. Diffuse conjunctival infiltration and scarring can give the conjunctiva a whitish and featureless appearance. In cicatricial (scarring) disease, symblepharon formation (adhesion between the palpebral and bulbar conjunctiva), shortening of the fornix (conjunctival sac), and caruncular keratinization (thickening of the caruncle, the small fleshy mound at the inner corner of the eye) may occur. Limbal papillae similar to those in VKC and Horner-Trantas dots can also be observed in AKC.

• Keratopathy in AKC: Punctate epithelial erosions (small defects on the corneal surface) are commonly observed in AKC, particularly in the inferior cornea. These erosions can be significant and persistent. Persistent epithelial defects can occur, potentially leading to corneal thinning, perforation, and descemetocele formation (protrusion of Descemet’s membrane, the deepest layer of the cornea). Corneal plaque formation can also be observed. Another common feature of AKC is stromal scarring and peripheral corneal vascularization, which tends to be more prevalent and severe than in VKC.

Untreated cases of AKC have a higher risk of developing secondary corneal infections, including bacterial and fungal keratitis. Occasionally, herpetic keratitis (herpes simplex virus infection of the cornea) can also develop as a complication of AKC.

Giant Papillary Conjunctivitis (GPC)

Symptoms of GPC can initially be similar to simple allergic conjunctivitis but often progress to become more severe and persistent. Patients may experience worsening eye itch, and the nature of the discharge may change from clear and watery to thick mucus. Additionally, they may report increased eye pain, redness, increased mucus production, contact lens intolerance (if contact lens-related), blurry vision, and a heightened foreign body sensation, particularly related to contact lenses or sutures. Symptoms usually worsen after contact lens removal in contact lens-related GPC.

Examination findings consistent with simple allergic conjunctivitis, such as conjunctival hyperemia and chemosis, are typically observed in GPC. However, the hallmark of GPC is the presence of giant papillae covering the tarsal conjunctiva, especially the superior tarsal conjunctiva. When evaluating a patient with suspected GPC, it is crucial to inquire about contact lens wear history, cleaning, and maintenance practices.

Various signs and features can be observed during the examination of papillary conjunctivitis. These include variable mucus production, proteinaceous deposits on contact lenses, excessive mobility of contact lenses on the eye, upper tarsal hyperemia, and papillae. Fine and medium-sized papillae are commonly seen in association with early GPC, while larger, giant papillae develop in more advanced cases. Focal areas of apical ulceration and white scarring may develop over the more prominent papillae due to mechanical trauma from blinking.

Keratopathy in GPC: Keratopathy, including punctate epithelial erosions and superficial corneal involvement, can occur in papillary conjunctivitis due to the release of inflammatory cytokines from the conjunctiva. Ptosis (drooping eyelid) can also occur in GPC due to tissue laxity, irritation, and spasms of tissues resulting from chronic inflammation in the affected area.

Evaluation

The diagnosis of allergic conjunctivitis is primarily clinical, relying on a thorough patient history and a comprehensive physical examination of the eyes and surrounding tissues.

In cases where corneal abrasion or injury is suspected, fluorescein staining of the cornea may be performed to rule out corneal epithelial defects. In certain cases, particularly when specific allergen identification is desired for avoidance strategies, skin prick testing or serum allergy testing may be helpful in identifying the causative allergens. Identifying the specific allergens can enable the implementation of appropriate avoidance measures, which can be crucial in mitigating the disease process and reducing symptom burden.

Simple Allergic Conjunctivitis: Conjunctival scraping for cytology may be performed in atypical cases of allergic conjunctivitis to examine for the presence of eosinophils, which are characteristic of allergic inflammation. While skin testing for allergens can be valuable in managing underlying atopy, it is rarely necessary for the diagnosis of simple allergic conjunctivitis itself, as the clinical presentation is often straightforward.

Vernal Keratoconjunctivitis: In cases of VKC, conjunctival scrapings typically reveal a high abundance of eosinophils, confirming the eosinophilic inflammatory nature of the condition.

Atopic Keratoconjunctivitis: Conjunctival scraping in AKC also reveals eosinophils, but generally in lower numbers compared to VKC. This difference in eosinophil counts can sometimes be a subtle differentiating feature between VKC and AKC, although clinical features are usually more decisive.

Differential Diagnosis of Allergic Conjunctivitis

The differential diagnosis for allergic conjunctivitis is broad, as many ocular conditions can present with overlapping symptoms such as redness, itching, and discharge. A careful history, thorough clinical examination, and sometimes ancillary testing are crucial to differentiate allergic conjunctivitis from other potential diagnoses. The key differential diagnoses to consider include:

1. Viral Conjunctivitis: Viral conjunctivitis is a highly contagious infection, often caused by adenovirus. Key differentiating features from allergic conjunctivitis include:

   • Discharge: Viral conjunctivitis typically presents with a watery discharge, similar to allergic conjunctivitis, but can sometimes become seromucoid.
   • Itching: Itching is less prominent in viral conjunctivitis compared to allergic conjunctivitis. A burning or gritty sensation is more common.
   • Preauricular lymphadenopathy: Swelling of the lymph nodes in front of the ear (preauricular lymphadenopathy) is a characteristic finding in viral conjunctivitis and is usually absent in allergic conjunctivitis.
   • Contagious nature: Viral conjunctivitis is highly contagious, and patients may report recent exposure to others with “pink eye.”
   • Absence of allergy history: Patients with viral conjunctivitis may not have a history of allergies or atopy.

2. Bacterial Conjunctivitis: Bacterial conjunctivitis is another infectious form of conjunctivitis, typically caused by bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, or Haemophilus influenzae. Differentiating features include:

   • Discharge: Bacterial conjunctivitis is characterized by a thick, purulent (pus-like) discharge that is often yellow or green. This discharge is significantly different from the watery or mucoid discharge in allergic conjunctivitis.
   • Crusting: Marked eyelid crusting, especially in the morning, is a prominent feature of bacterial conjunctivitis.
   • Lack of itching: Itching is typically minimal or absent in bacterial conjunctivitis. Patients may complain of a gritty or burning sensation.
   • Unilateral onset: Bacterial conjunctivitis often starts in one eye and can spread to the other eye, but unilateral presentation is more common initially than in allergic conjunctivitis, which is usually bilateral.

3. Molluscum Contagiosum Conjunctivitis: Molluscum contagiosum is a viral skin infection that can affect the eyelids and conjunctiva. Differential points include:

   • Skin lesions: Molluscum contagiosum is characterized by distinctive, pearly, umbilicated skin nodules on the eyelids or eyelid margins. These nodules are not present in allergic conjunctivitis.
   • Chronic follicular conjunctivitis: Molluscum infection can cause a chronic follicular conjunctivitis, which may mimic some forms of allergic conjunctivitis, but the presence of skin lesions is a key differentiating factor.

4. Giant Fornix Syndrome: Giant fornix syndrome is a rare condition characterized by chronic conjunctivitis and the formation of a large conjunctival fornix (the recess formed where the palpebral and bulbar conjunctiva meet). Key differences are:

   • Deep fornix: The presence of an abnormally deep conjunctival fornix, often containing debris or concretions, is diagnostic of giant fornix syndrome.
   • Chronic, indolent course: Giant fornix syndrome tends to be a chronic, slowly progressive condition, unlike the episodic exacerbations often seen in allergic conjunctivitis.

5. Adult Chlamydial Conjunctivitis (Paratrachoma): Adult inclusion conjunctivitis is caused by Chlamydia trachomatis and is often sexually transmitted. Distinguishing features include:

   • Follicular conjunctivitis: Chlamydial conjunctivitis typically presents with a prominent follicular reaction in the conjunctiva, particularly in the inferior fornix.
   • Scanty mucopurulent discharge: The discharge is usually mucopurulent but often less copious than in bacterial conjunctivitis.
   • Corneal involvement: Superficial punctate keratitis and superior corneal pannus (vascularization) can occur in chlamydial conjunctivitis.
   • Genital infection: Patients may have a history or concurrent symptoms of genital chlamydial infection.

6. Trachoma: Trachoma is a chronic keratoconjunctivitis caused by Chlamydia trachomatis, endemic in certain regions and a leading cause of preventable blindness worldwide. Key differences from allergic conjunctivitis include:

   • Endemic area: Trachoma is primarily seen in areas with poor sanitation and hygiene. Travel history is important.
   • Follicles and papillae: Trachoma causes both follicles and papillae, particularly in the superior tarsal conjunctiva.
   • Corneal scarring and pannus: Trachoma leads to progressive corneal scarring, superior pannus, and trichiasis (inward turning of eyelashes).
   • Absence of itching: Itching is not a prominent symptom of trachoma.

7. Neonatal Conjunctivitis (Ophthalmia Neonatorum): Conjunctivitis in newborns can be caused by various pathogens, including Neisseria gonorrhoeae, Chlamydia trachomatis, and bacteria. Differential diagnosis is crucial due to potential sight-threatening complications.

   • Age of onset: Neonatal conjunctivitis occurs within the first month of life.
   • Type of discharge: Gonococcal conjunctivitis presents with hyperpurulent discharge, while chlamydial conjunctivitis has a more watery or mucopurulent discharge.
   • Maternal history: Maternal history of sexually transmitted infections is a risk factor.

8. Nonallergic Eosinophilic Conjunctivitis: This is a rare form of chronic conjunctivitis characterized by eosinophilic inflammation but without a clear allergic trigger.

   • Eosinophils on cytology: Conjunctival cytology shows eosinophils, similar to allergic conjunctivitis.
   • Lack of allergy history: Patients do not have a typical allergy history or atopic background.
   • Refractory to allergy treatments: Nonallergic eosinophilic conjunctivitis may be less responsive to conventional allergy treatments.

9. Contact Allergic Blepharoconjunctivitis: Contact dermatitis of the eyelids and conjunctiva can be caused by topical medications, cosmetics, or other contact allergens.

   • History of exposure: History of new topical products, cosmetics, or medications used around the eyes is crucial.
   • Eyelid dermatitis: Erythema, scaling, and vesicles on the eyelids are characteristic of contact dermatitis.
   • Distribution: Conjunctivitis may be more localized to areas of contact with the allergen.

10. Mucous Membrane Pemphigoid (MMP): Ocular cicatricial pemphigoid is a chronic, autoimmune blistering disease affecting mucous membranes, including the conjunctiva. It’s a serious condition that can lead to blindness.

    • Subepithelial fibrosis and scarring: MMP causes progressive conjunctival scarring, symblepharon formation, and forniceal shortening.
    • Dry eye: Severe dry eye is a common feature due to destruction of conjunctival goblet cells.
    • Lack of itching: Itching is not a prominent symptom.
    • Older age group: MMP typically affects older individuals.

11. Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN): These are severe mucocutaneous reactions, often drug-induced, that can involve the conjunctiva.

    • Systemic illness: SJS/TEN is a systemic disease with skin and mucous membrane involvement.
    • Skin blisters and erosions: Characteristic skin lesions, including bullae and erosions, are present.
    • Severe conjunctivitis: Conjunctivitis in SJS/TEN is severe and can lead to scarring and vision loss.
    • Medication history: Recent use of medications known to trigger SJS/TEN is a key historical point.

12. Superior Limbic Keratoconjunctivitis (SLK): SLK is a chronic inflammatory condition affecting the superior bulbar conjunctiva and superior cornea.

    • Superior conjunctival and corneal involvement: Inflammation is localized to the superior limbus, bulbar conjunctiva, and cornea.
    • Filamentary keratitis: Corneal filaments are a characteristic finding.
    • Lack of allergy association: SLK is not typically associated with allergy.

13. Ligneous Conjunctivitis: Ligneous conjunctivitis is a rare form of chronic pseudomembranous conjunctivitis associated with plasminogen deficiency.

    • Pseudomembranes: Formation of thick, woody pseudomembranes on the conjunctiva is the hallmark of ligneous conjunctivitis.
    • Recurrent: Pseudomembranes recur after removal.
    • Systemic involvement: Ligneous conjunctivitis can be associated with systemic plasminogen deficiency and involvement of other mucous membranes.

14. Parinaud Oculoglandular Syndrome: This syndrome is characterized by unilateral granulomatous conjunctivitis and regional lymphadenopathy, often caused by cat-scratch disease, tularemia, or other infections.

    • Unilateral granulomatous conjunctivitis: Conjunctivitis is typically unilateral and granulomatous in nature.
    • Regional lymphadenopathy: Enlarged and tender regional lymph nodes are a key feature.
    • History of animal contact: History of cat scratch or animal exposure may be present in cat-scratch disease or tularemia.

15. Factitious Conjunctivitis: Factitious conjunctivitis is a self-inflicted condition where patients intentionally irritate their eyes, often for psychological reasons.

    • Unexplained chronic conjunctivitis: Chronic conjunctivitis that does not respond to treatment and lacks objective findings.
    • Discrepancy between symptoms and signs: Symptoms may be exaggerated compared to clinical signs.
    • Psychological factors: Underlying psychological issues may be present.

Accurate differential diagnosis is crucial for appropriate management and to prevent potential complications or vision loss from mimicking conditions. A systematic approach, considering history, clinical features, and targeted investigations when needed, is essential in differentiating allergic conjunctivitis from its mimics.

Treatment / Management

Simple Allergic Conjunctivitis

Patient education is paramount in the management of all forms of allergic conjunctivitis, including simple allergic conjunctivitis. Patients should be advised to avoid rubbing their eyes, as this action can exacerbate mast cell degranulation and worsen symptoms. Frequent application of artificial tears and cool compresses can provide significant symptomatic relief.

Whenever possible, patients should avoid known allergen exposures. If contact lens wear is a trigger or exacerbating factor, temporary discontinuation is advisable. For mild, acute episodes of simple allergic conjunctivitis, over-the-counter antihistamine and vasoconstrictor combination eye drops can be used for short durations to relieve redness and itching. However, patients should be cautioned about the potential for rebound conjunctival injection (rhinitis medicamentosa-like effect in the eye) if vasoconstrictor drops are used for extended periods.

For seasonal and perennial allergic conjunctivitis, a combination of antihistamine and mast cell stabilizing topical drops is often the first-line recommendation. Topical nonsteroidal anti-inflammatory (NSAID) drops can provide some symptomatic relief by reducing inflammation but are generally less effective than antihistamines or mast cell stabilizers for controlling itch and allergic symptoms.

In refractory cases of simple allergic conjunctivitis, short courses of topical corticosteroid drops (typically less than 2 weeks) may be considered. However, steroid use should be under the close supervision of an eye care specialist with appropriate follow-up monitoring due to the potential for steroid-related side effects. Systemic antihistamines and oral steroids have limited roles in the routine treatment of simple allergic conjunctivitis and are generally reserved for cases with significant systemic allergic symptoms rather than isolated ocular involvement.

The overall treatment approach to allergic conjunctivitis generally follows a step-ladder approach based on symptom severity. For mild symptoms, artificial tears alone may be sufficient. Mast cell stabilizers, such as sodium cromoglycate, nedocromil sodium, and lodoxamide, are effective for long-term management and prevention of symptoms. However, their maximal effect is typically seen after several days to weeks of continuous use, making them more suitable for prophylactic or maintenance therapy.

Antihistamine eye drops, such as emedastine, epinastine, bepotastine, and levocabastine, are commonly used for acute exacerbations and provide rapid relief of itching and redness. They are generally as effective as mast cell stabilizers for acute symptom control. For more severe and recurrent cases, combination drops containing both antihistamines and vasoconstrictors, such as antazoline and xylometazoline, may be prescribed to provide more comprehensive symptom relief.

Topical NSAIDs can be effective in reducing inflammation and providing symptomatic relief, particularly for pain and discomfort.

Topical corticosteroids are highly effective for relieving acute exacerbations and controlling inflammation. However, their use should be limited to short durations and under specialist guidance due to potential side effects like glaucoma and cataract formation.

When systemic symptoms are significant or topical treatment is insufficient, oral antihistamines, such as diphenhydramine and loratadine, may be used. Loratadine is often preferred over diphenhydramine due to its lower sedative potential, making it a better option for daytime use.

Vernal and Atopic Keratoconjunctivitis

The management principles for VKC and AKC are generally similar, but AKC typically requires more intensive and prolonged treatment compared to VKC due to its chronic and often more severe nature.

Patient education remains crucial for VKC and AKC. This includes advising patients on general allergic eye care measures, such as frequent use of artificial tears and cool compresses, minimizing allergen exposure, and strictly avoiding eye rubbing.

Initial pharmacotherapy for both VKC and AKC typically involves topical combination antihistamine and mast cell stabilizing drops, similar to the treatment used for seasonal and perennial allergic conjunctivitis. These combination drops provide both rapid symptom relief and longer-term control of allergic inflammation.

In refractory VKC or AKC cases that do not respond adequately to initial therapies, referral to an ophthalmologist specializing in cornea and external diseases is recommended. These specialists may prescribe topical corticosteroids to manage severe inflammation and corneal involvement. If the patient continues to be refractory to treatment or cannot be weaned off topical steroid therapy due to recurrent exacerbations, topical or systemic calcineurin inhibitors, such as topical cyclosporine or tacrolimus, can be considered as steroid-sparing alternative therapeutic options for long-term management.

General Treatment Measures for Allergic Conjunctivitis

The primary goal in managing all types of allergic conjunctivitis, including VKC and AKC, is to minimize or avoid exposure to the specific allergen(s) that trigger the allergic response. Allergen avoidance strategies may include environmental control measures, such as air purifiers, allergen-proof bedding, and avoiding exposure to pollen, pet dander, or dust mites. In some severe cases, eye patching may be temporarily required to protect the ocular surface and reduce irritation. Consultation with a cornea specialist is advisable in complex or severe cases to determine the most appropriate management approach.

Cold compresses applied to the closed eyelids can provide significant relief from inflammation, itching, and discomfort. Maintaining good eyelid hygiene is also essential, particularly in AKC and GPC, to prevent and manage associated staphylococcal blepharitis and eyelid margin disease. Warm compresses and gentle eyelid scrubs can help improve meibomian gland function and reduce eyelid inflammation.

For patients with dry and fissured skin around the eyes, particularly in AKC, using a bland moisturizing cream, such as petrolatum-based ointments or hypoallergenic moisturizers, can help keep the skin hydrated, reduce dryness and itching, and improve overall comfort.

In cases of persistent epithelial defects or corneal ulcers, a bandage contact lens may be recommended as part of the treatment plan. The bandage contact lens acts as a protective barrier over the cornea, promoting epithelial healing and reducing pain and discomfort.

Medical Management: Topical and Systemic Medications

Mast Cell Stabilizers: Topical mast cell stabilizers, including sodium cromoglicate, nedocromil sodium, and lodoxamide, are essential medications in the long-term management of allergic conjunctivitis, including VKC and AKC. They play a crucial role in controlling allergic symptoms and reducing the need for steroid use, making them important components of many treatment regimens, particularly for maintenance therapy. However, these medications are often not as effective when used alone for acute symptom relief and are typically combined with other treatments, such as antihistamines, for optimal effect.

In cases of VKC and AKC, consistent treatment with mast cell stabilizers may be required for several weeks to achieve significant clinical improvement, and long-term maintenance therapy is often necessary to sustain symptom control and prevent exacerbations. It is important to note that lodoxamide is not FDA-approved for long-term use, and other mast cell stabilizers may be preferred for prolonged therapy.

Topical Antihistamines: Topical antihistamine eye drops, such as emedastine, epinastine, levocabastine, and bepotastine, are all effective in rapidly relieving the acute symptoms of allergic conjunctivitis, including itching, redness, and tearing in VKC and AKC. Some topical antihistamines, such as epinastine and bepotastine, also possess mast cell stabilizing properties, providing a dual mechanism of action.

Topical antihistamines are an excellent choice for providing quick symptom relief during acute exacerbations of allergic conjunctivitis. However, for long-term control of inflammation and to reduce dependence on steroids, medications with mast cell stabilizing properties, such as sodium cromoglycate, nedocromil sodium, lodoxamide, or combination antihistamine/mast cell stabilizer drops, may be required for sustained therapy.

Combination medications, including both antihistamine and mast cell stabilizer components in a single formulation (e.g., ketotifen, olopatadine, azelastine/fluticasone), can be particularly effective in managing allergic conjunctivitis, including VKC and AKC. These combination drops provide both rapid symptom relief from the antihistamine component and longer-term control of allergic inflammation from the mast cell stabilizer component. In some instances, vasoconstrictors like xylometazoline and antazoline may be combined with antihistamines in over-the-counter preparations to provide additional relief from redness and congestion, but their use should be limited to short durations due to rebound hyperemia risk.

Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Topical nonsteroidal anti-inflammatory drugs (NSAIDs), such as ketorolac, diclofenac, nepafenac, and bromfenac, can provide symptomatic relief and improve patient comfort by blocking non-histamine inflammatory mediators involved in the allergic response, particularly prostaglandins. For some patients, combining a topical NSAID with a mast cell stabilizer has proven to be an effective drug therapy for managing allergic conjunctivitis, particularly for reducing pain and inflammation.

Topical Corticosteroids: Topical corticosteroids are highly effective and essential in managing severe acute exacerbations of allergic conjunctivitis, controlling significant inflammation, and treating keratopathy associated with VKC and AKC. Commonly used topical steroids include fluorometholone 0.1%, loteprednol etabonate 0.2% and 0.5%, rimexolone 1%, and prednisolone acetate 1%.

To effectively manage severe inflammation and associated corneal pathology in VKC and AKC, a short and intense course of topical steroid therapy with an hourly or frequent dosing regimen may be required initially, followed by a careful and gradual tapering schedule to minimize rebound inflammation and steroid-related side effects. This approach helps rapidly reduce conjunctival inflammation, leading to an improvement in corneal health and symptom relief.

It is crucial to closely monitor patients receiving topical steroids for potential adverse effects, particularly elevation of intraocular pressure (IOP) and the development of steroid-induced glaucoma and cataracts, especially with prolonged use. Regular IOP checks and monitoring for cataract formation are essential during topical steroid therapy.

Some clinicians may prefer to use steroid eye ointments, such as beclomethasone or hydrocortisone 0.5%, particularly for managing AKC with significant eyelid involvement. However, strict IOP control and monitoring should still be implemented during steroid ointment treatment due to systemic absorption and potential for IOP elevation.

Topical Antibiotics: In cases of severe keratopathy associated with allergic conjunctivitis, particularly if corneal epithelial defects or ulcers are present, a combination antibiotic and steroid eye drop formulation may be necessary to manage the condition effectively and prevent the development of secondary bacterial keratitis. This combination therapy helps address both the inflammatory component and the risk of secondary bacterial infection, promoting corneal healing and reducing the risk of infectious complications.

Mucolytic Agents: Topical mucolytic agents, such as acetylcysteine, can be useful in VKC and AKC for dissolving thick mucus filaments, mucus deposits, and early plaque formation on the conjunctiva and cornea. Acetylcysteine helps to break down disulfide bonds in mucus glycoproteins, reducing mucus viscosity and facilitating clearance of mucus from the ocular surface, improving vision and comfort.

Immunomodulators: Calcineurin Inhibitors: Topical immunomodulators, particularly calcineurin inhibitors such as cyclosporine (0.05%-2%) and tacrolimus 0.03% eye ointment, may be needed in cases of severe VKC and AKC with a suboptimal response to topical steroids, when steroids are ineffective, poorly tolerated due to side effects, or when steroid dependence develops. Calcineurin inhibitors act as steroid-sparing agents in patients with severe, chronic allergic conjunctivitis, reducing the need for prolonged or high-dose steroid therapy.

Topical cyclosporine is typically used 2 to 6 times daily, while tacrolimus 0.03% eye ointment is usually instilled at bedtime in the conjunctival fornices. Immunomodulators generally take several weeks (approximately 6 weeks or longer) to achieve their full therapeutic effect, and there can be rebound inflammation if the drug is stopped abruptly. Common side effects of topical cyclosporine and tacrolimus include blurred vision and transient ocular irritation.

Supratarsal Steroid Injection: Supratarsal steroid injection may be considered in patients with severe palpebral VKC who are unresponsive to topical steroids or who are non-compliant with topical therapy. In this procedure, the conjunctiva is everted, and a small injection of corticosteroid is administered into the supratarsal conjunctiva (the conjunctiva above the tarsal plate). Commonly used steroids for supratarsal injection include betamethasone 4 mg/mL, dexamethasone 4 mg/mL, or triamcinolone acetonide. Supratarsal steroid injection provides a depot effect, delivering a sustained dose of steroid to the affected tarsal conjunctiva, reducing inflammation and giant papillae formation.

Systemic Medications:

Oral Antihistamines: Oral antihistamines can be administered to help resolve systemic allergic symptoms and may provide some adjunctive relief of ocular itching in allergic conjunctivitis. However, their effectiveness for isolated ocular symptoms is often limited. Oral antihistamines can induce systemic side effects, such as drowsiness and dry mouth, which may be undesirable for some patients. However, the sedative effect of some oral antihistamines can be beneficial in reducing nighttime itching and eye rubbing, improving sleep quality. Less sedating oral antihistamines, such as loratadine, fexofenadine, and cetirizine, are often preferred for daytime use.

Oral Antibiotics: Oral antibiotics, such as doxycycline (50 to 100 mg once daily for 6 weeks) and azithromycin (500 mg once daily for 3 days), can be used in AKC, particularly when associated with significant blepharitis and meibomian gland dysfunction. These antibiotics have anti-inflammatory properties and can help reduce eyelid inflammation and improve meibomian gland function, which can exacerbate ocular surface inflammation in AKC.

Oral Immunosuppressants: Systemic immunosuppressants, including oral corticosteroids, cyclosporine, tacrolimus, and azathioprine, may be considered in low doses for severe, refractory allergic conjunctivitis, particularly AKC, that is unresponsive to topical therapies. A short course of high-dose oral steroids may be required initially to achieve rapid control of severe disease exacerbations. Monoclonal antibodies, such as omalizumab (anti-IgE antibody), may be helpful in highly refractory cases of allergic conjunctivitis with elevated IgE levels. Aspirin has also been tried in patients with VKC for its anti-inflammatory effects, but its use in children should be cautious due to the risk of Reye syndrome. Other systemic measures used in highly refractory cases include allergen desensitization (allergen immunotherapy) and plasmapheresis in patients with very high IgE levels.

Topical Drug Delivery with Contact Lenses: After contact lens removal in GPC, instilling mast cell stabilizers or combination antihistamine/mast cell stabilizer drops can help relieve itching and inflammation. In some instances of allergic conjunctivitis, long-term use of mast cell stabilizers may be necessary to effectively manage and control symptoms. Topical NSAIDs and combined antihistamine and mast cell stabilizer eye drops can also be beneficial in managing allergic conjunctivitis symptoms associated with contact lens wear. If acute exacerbations occur or the condition is resistant to other treatments, short-term topical steroids may be necessary for their potent anti-inflammatory effects, but steroid use should be carefully monitored by an eye care professional.

Surgical Measures:

Surgical management is rarely required in cases of allergic conjunctivitis. However, in specific situations where surgical intervention is deemed necessary, such as cases with severe corneal involvement or complications, certain surgical procedures may be considered:

• Glue and Bandage Contact Lenses: Cyanoacrylate glue application with bandage contact lenses may be required in patients with small corneal perforations secondary to severe keratopathy in AKC or VKC to seal the perforation and promote corneal healing.

• Superficial Keratectomy: Superficial keratectomy may be needed in cases with shield ulcers in VKC for debridement and removal of corneal plaques and necrotic tissue, facilitating corneal re-epithelialization. Topical medications should be continued postoperatively to prevent ulcer recurrence.

• Phototherapeutic Keratectomy (PTK): Phototherapeutic keratectomy using an excimer laser is another alternative surgical option for removing corneal plaques and superficial corneal opacities in VKC and AKC, improving corneal surface regularity and vision.

• Amniotic Membrane Grafting (AMG): Amniotic membrane grafting may be required in cases of persistent epithelial defects or corneal ulcers in severe AKC or VKC that are unresponsive to conventional medical therapy. AMG provides a biological scaffold that promotes corneal epithelial healing, reduces inflammation, and prevents corneal scarring.

• Lamellar Keratoplasty or Patch Graft: In severe cases of corneal thinning, descemetocele formation, or corneal perforation in AKC or VKC, lamellar keratoplasty (partial thickness corneal transplant) or patch graft (corneal tissue graft) may be considered to restore corneal structural integrity and prevent vision loss.

• Botox-Induced Ptosis: Botulinum toxin (Botox) injection to induce temporary ptosis (eyelid drooping) has been used as a management option for persistent epithelial defects in severe AKC or VKC. Ptosis reduces corneal exposure, promoting epithelial healing.

Giant Papillary Conjunctivitis (GPC) Management

The primary initial step in managing giant papillary conjunctivitis is to remove the mechanical irritant, which is most commonly contact lenses. Patients should discontinue contact lens wear for a few weeks to allow the conjunctival inflammation to subside. When contact lens wear is resumed, refitting with a different lens type, material, or wearing schedule may be necessary to avoid re-exposure to the inciting factors. General allergic eye care measures should be practiced, such as avoiding eye rubbing, using artificial tears and cool compresses for symptomatic relief, and allergen avoidance.

Initial pharmacotherapy for GPC is similar to other types of ocular allergies, with options including topical antihistamines or a combination of an antihistamine and mast cell stabilizing drops to alleviate symptoms. These drops help reduce itching, redness, and papillary inflammation.

In more severe and refractory cases of GPC, topical corticosteroid drops can be prescribed under the supervision of an eye care specialist, similar to the treatment approach for vernal and atopic keratoconjunctivitis. However, calcineurin inhibitors are generally not considered first-line agents in the treatment of GPC and are not typically used unless other therapies fail. In cases of GPC associated with sutures or scleral buckles, surgical removal of these devices may be necessary to reduce mechanical irritation and resolve the condition. Regular assessment of ocular prosthesis condition and fitting is crucial in patients with prosthesis-related GPC.

For GPC associated with filtering blebs after glaucoma surgery, surgical intervention, such as bleb revision or nonpenetrating glaucoma drainage surgery followed by glaucoma drainage device implantation, may be required to address the bleb-related irritation and GPC. To prevent contact lens papillary conjunctivitis (CLPC), patients should be educated on proper contact lens cleaning and maintenance practices, including regular cleaning, disinfection, and lens case hygiene. Switching to preservative-free contact lens solutions and transitioning to more frequent lens replacement schedules, such as monthly or daily disposable contact lenses, is often recommended.

Rigid gas permeable (RGP) contact lenses carry a lower risk of CLPC compared to soft contact lenses because they are easier to clean and accumulate less protein deposits. In some cases, complete cessation of contact lens wear and substitution with spectacles may be necessary. Rare cases of severe, refractory GPC may require refractive surgery to eliminate the need for contact lenses. Protein removal tablets can be used to enhance cleaning and removal of protein deposits from reusable contact lenses. For ocular prostheses, regular washing and cleaning with detergent and application of a protective coating are essential to maintain hygiene, reduce irritation, and prevent GPC recurrence.

Staging of Vernal Keratoconjunctivitis

Vernal keratoconjunctivitis (VKC) severity can be staged using various clinical grading systems to guide treatment and monitor disease progression. Two commonly used staging systems are the Bonini Clinical Staging and the Gokhale Staging of Vernal Keratoconjunctivitis.

Table 1. Bonini Clinical Staging of Vernal Keratoconjunctivitis

Stage	Conjunctival Papillae	Corneal Involvement	Symptoms
Stage 1 (Mild)	Mild papillae, <1 mm	No corneal involvement or mild punctate epithelial erosions	Mild itching, occasional tearing
Stage 2 (Moderate)	Moderate papillae, 1-3 mm	Moderate punctate epithelial erosions, early shield ulcer	Moderate itching, tearing, photophobia
Stage 3 (Severe)	Giant papillae, >3 mm	Shield ulcer, corneal plaque, stromal scarring	Severe itching, tearing, photophobia, blurred vision

Table 2. Gokhale Staging of Vernal Keratoconjunctivitis

Stage	Papillae	Limbal Involvement	Corneal Involvement
Stage 1	Mild tarsal papillae	No limbal involvement	No corneal involvement
Stage 2	Moderate tarsal papillae	Mild limbal papillae or Trantas dots	Punctate epithelial erosions
Stage 3	Giant tarsal papillae	Significant limbal papillae or Horner-Trantas dots	Shield ulcer or corneal plaque
Stage 4	Cicatricial VKC	Extensive limbal involvement with stem cell deficiency	Corneal scarring, neovascularization, vision loss

These staging systems help clinicians assess the severity of VKC, guide treatment decisions, and monitor treatment response over time. More severe stages typically require more aggressive and prolonged treatment, including topical corticosteroids or immunomodulators.

Prognosis

In most patients with simple allergic conjunctivitis (SAC and PAC), the prognosis is generally excellent. Complications are rare, and most individuals achieve good symptom control with appropriate management. However, there is a possibility of symptom recurrence, particularly with seasonal allergens.

For patients with more severe forms of allergic conjunctivitis, such as vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC), the prognosis is more variable. While VKC often improves spontaneously by late adolescence, AKC tends to be a chronic, relapsing condition that can persist into adulthood. Complications, such as corneal damage, are more common in VKC and AKC and can lead to visual impairment if not properly managed. Additionally, long-term use of medications, particularly topical corticosteroids, to manage severe allergic conjunctivitis can be associated with the development of cataracts and glaucoma. Regular monitoring and careful management are essential to optimize visual outcomes and minimize complications in VKC and AKC.

Complications

In most cases, allergic conjunctivitis is not a serious threat to overall health and is considered a common and often benign condition. However, although complications are rare, when they do occur, they can be severe and potentially sight-threatening, especially in VKC and AKC. Potential complications of allergic conjunctivitis include:

• Corneal Scarring: Severe and chronic inflammation in VKC and AKC can lead to corneal scarring, which can impair vision, particularly if the central cornea is involved.

• Progression to Infective Conjunctivitis: Although allergic conjunctivitis itself is not infectious, chronic ocular surface inflammation can increase susceptibility to secondary bacterial, viral, or fungal infections, leading to infective conjunctivitis or keratitis.

• Conjunctival Scarring and Symblepharon: In severe AKC and mucous membrane pemphigoid, conjunctival scarring and symblepharon (adhesion between conjunctival surfaces) can occur, leading to forniceal shortening and restricted eye movement.

• Bacterial Keratitis: Corneal epithelial defects and ulcers in VKC and AKC increase the risk of bacterial keratitis, a serious corneal infection that can cause corneal perforation and vision loss.

• Corneal Neovascularization and Pannus: Chronic corneal inflammation, particularly in AKC and trachoma, can stimulate abnormal blood vessel growth into the cornea (neovascularization) and pannus formation (superficial fibrovascular tissue on the cornea), which can opacify the cornea and impair vision.

• Giant Papillae and Shield Ulcer: Giant papillae in VKC can cause mechanical trauma to the corneal epithelium, leading to shield ulcer formation, a chronic, indolent corneal ulcer covered by a plaque of mucus and cellular debris.

• Nonresolving Epithelial Defect: Persistent corneal epithelial defects in severe AKC and VKC can be challenging to manage and increase the risk of corneal infection and scarring.

• Steroid-Induced Glaucoma and Cataracts: Prolonged use of topical corticosteroids, particularly potent steroids, to treat severe allergic conjunctivitis can lead to steroid-induced glaucoma (increased intraocular pressure) and posterior subcapsular cataracts, both of which can cause vision loss.

• Dry Eyes: Chronic conjunctival inflammation, especially in AKC and mucous membrane pemphigoid, can damage conjunctival goblet cells, leading to tear film dysfunction and dry eye syndrome, exacerbating ocular surface discomfort.

• Keratoconus: There is an association between atopic disease, including AKC, and keratoconus, a progressive corneal ectasia characterized by corneal thinning and distortion. Chronic eye rubbing in allergic conjunctivitis may be a contributing factor to keratoconus development.

• Herpetic Keratitis: Patients with AKC may have an increased risk of herpetic keratitis (herpes simplex virus infection of the cornea) due to ocular surface inflammation and immune dysregulation.

Early diagnosis, appropriate management, and regular monitoring are essential to minimize the risk of complications in allergic conjunctivitis, particularly in severe and chronic forms like VKC and AKC.

Postoperative and Rehabilitation Care

Surgical management is rarely required in cases of allergic conjunctivitis. However, in specific situations where surgical intervention is deemed necessary, such as cases with severe corneal involvement or complications like shield ulcers, amniotic membrane grafting, lamellar keratoplasty, or patch graft may be considered.

Postoperatively, tapering doses of topical steroids are typically initiated to control postoperative inflammation and promote healing. Patients should be thoroughly educated about the potential short-term and long-term side effects of steroid medications, including the risks of glaucoma and cataracts with prolonged use. Regular follow-up visits are crucial in the postoperative period to closely monitor the healing process, evaluate the effectiveness of treatment, detect and manage any complications, and minimize the risk of acute exacerbations or recurrence of allergic conjunctivitis. Postoperative rehabilitation may include continued use of artificial tears, topical mast cell stabilizers, and allergen avoidance measures to maintain long-term ocular surface health and prevent symptom recurrence.

Consultations

Patients presenting with symptoms of eye pain, redness, and itching should undergo a comprehensive eye examination to evaluate for clinical signs of allergic conjunctivitis. General ophthalmologists and optometrists should be proficient in the diagnosis and initial treatment of allergic conjunctivitis, as it is a common condition encountered in routine clinical practice.

When the diagnosis is uncertain, or if complications develop, referral to a cornea and external disease specialist is recommended for further evaluation and specialized management. Patients with severe VKC or AKC, those with corneal involvement (shield ulcers, persistent epithelial defects, corneal scarring), and those who are unresponsive to initial therapies should be referred to a cornea specialist. If a patient develops secondary glaucoma as a complication of steroid use, involving a glaucoma specialist in the care team is essential to provide appropriate management of glaucoma and prevent further optic nerve damage and vision loss. Similarly, patients with shield ulcers or other complex corneal complications should be managed in consultation with a cornea expert.

Deterrence and Patient Education

Prevention plays a crucial role in the effective long-term management of allergic conjunctivitis. Identifying specific allergen triggers through allergy skin tests performed by allergists can be highly beneficial in creating a targeted and personalized preventive strategy. By knowing the specific allergens that trigger their allergic reactions, patients can take proactive steps to minimize or avoid exposure to these triggers, reducing the frequency and severity of allergic conjunctivitis episodes. Allergen avoidance measures may include environmental control (air purifiers, allergen-proof bedding, etc.), avoiding outdoor activities during high pollen counts, and pet avoidance if pet dander is a trigger.

Patient education is paramount in the successful management of allergic conjunctivitis. Clearly explaining the chronic nature of the condition, its potential complications if untreated, and the importance of adherence to prescribed medications are essential components of patient education. Patients should be well-informed about the various treatment options available, including topical medications, systemic medications, and non-pharmacological measures, and how to use these treatments effectively and safely. Education should also emphasize the importance of regular follow-up eye examinations to monitor disease progression, treatment response, and potential complications. Patients should be instructed on proper instillation techniques for eye drops, potential side effects of medications, and when to seek prompt medical attention for worsening symptoms or new concerns.

Pearls and Other Issues

Allergic conjunctivitis encompasses a spectrum of clinical manifestations, including acute seasonal and perennial forms, as well as more severe subtypes like atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), and giant papillary conjunctivitis (GPC). Healthcare practitioners should be able to recognize and differentiate between these subtypes based on a thorough patient evaluation, detailed history taking, and careful clinical examination findings. In cases of GPC, it is particularly important to inquire about the patient’s history of contact lens use, as contact lens wear is a significant contributing factor to GPC development.

When managing patients with allergic conjunctivitis, it is essential to educate them about the chronic nature of the condition and the potential need for long-term medication use to maintain symptom control. Patients should be informed about the potential for waxing and waning of symptoms over time, with periods of exacerbation and remission. Emphasizing the importance of regular follow-up appointments with their eye care provider and consistent medication compliance, even during periods of symptom quiescence, is vital in ensuring effective long-term disease management and preventing potential complications and vision loss. Open communication between the patient and healthcare provider, with prompt reporting of any worsening symptoms or new concerns, is crucial for optimal outcomes in allergic conjunctivitis management.

Enhancing Healthcare Team Outcomes

Most patients with allergic conjunctivitis are initially seen by a range of healthcare professionals, including pharmacists, nurse practitioners, and primary care providers. Patients often initially seek over-the-counter treatments for their symptoms at the pharmacy, providing pharmacists with a valuable opportunity to provide patient education and guidance. Pharmacists should take the initiative to educate patients about lifestyle modifications and environmental control measures that can help manage allergies effectively and reduce symptom burden. Pharmacists should also be able to recognize red flag symptoms and appropriately refer patients with severe or recurrent symptoms, or those with suspected complications, to an ophthalmologist or optometrist for further evaluation and specialized care.

Patients with allergic conjunctivitis should be educated on the importance of avoiding offending allergens, which may necessitate lifestyle changes and environmental modifications to effectively manage their condition. Some patients may benefit from allergy testing to identify specific allergen triggers, enabling them to modify their behavior and environment accordingly to minimize allergen exposure.

Contact lens wear may not be suitable for some individuals with allergic conjunctivitis, particularly those with GPC or severe ocular surface disease. These patients may need to consider alternative eyewear options, such as spectacles or refractive surgery. All patients with allergic conjunctivitis should receive comprehensive education on various measures to alleviate symptoms and minimize exposure to allergens. These recommendations may include strategies such as using humidifiers in the home to reduce indoor allergens, wearing sunglasses when outdoors to minimize pollen and UV exposure, avoiding mascara and eye makeup during active allergic episodes, using artificial tears liberally to lubricate the ocular surface and wash away allergens, and applying cold compresses to the eyes to reduce inflammation and itching.

While healthcare practitioners, such as primary care providers and nurse practitioners, may encounter patients with allergic conjunctivitis in outpatient settings, it is essential to remain vigilant for any visual changes or severe symptoms that could indicate a more serious underlying condition or complications of allergic conjunctivitis. Empirical prescription of topical steroids by non-eye care specialists is generally not recommended, as these agents have potential side effects, including the development of cataracts and glaucoma, and should be used under the supervision of an eye care professional.

The potential for misdiagnosis or mistaking allergic conjunctivitis for a more severe condition highlights the importance of vigilance and effective communication among the entire healthcare team. Nurses, pharmacists, and other healthcare professionals who interact directly with the patient should remain watchful for any signs of poor response to treatment or worsening symptoms. Prompt reporting of any concerns to the clinical team’s interprofessional leader, such as the ophthalmologist or optometrist, is essential for timely intervention and appropriate management adjustments.

Patient education is crucial for improving healthcare team outcomes in allergic conjunctivitis management. Healthcare professionals should inform patients about the need for close follow-up if symptom improvement does not occur quickly with initial therapies. Encouraging patients to actively report any new or worsening symptoms, especially the development of eye pain, changes in vision, or purulent discharge, is essential for early intervention and appropriate management of potential complications.

An interprofessional team approach involving open communication, shared decision-making, and joint patient education leads to the best possible care and outcomes for patients with allergic conjunctivitis. By working collaboratively, the healthcare team can identify potential treatment failures early on, prevent the development of significant morbidity and vision loss, and optimize patient quality of life.

Outcomes of Allergic Conjunctivitis Management

The long-term outcomes for patients with perennial allergic conjunctivitis (PAC) and seasonal allergic conjunctivitis (SAC) are generally favorable. Most individuals achieve good symptom control with appropriate management and experience minimal long-term visual sequelae. However, many patients continue to experience some degree of eye discomfort and may have suboptimal ocular cosmesis due to chronic redness or eyelid changes. Some patients may develop recurrent episodes of conjunctivitis, and in rare cases, chronic limbal conjunctival chemosis can lead to conjunctivochalasis (redundancy of the conjunctiva).

In more severe cases of allergic conjunctivitis, such as vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC), there is a higher risk of complications and potentially less favorable long-term outcomes. Corneal opacification and ulcer formation can occur in VKC and AKC, potentially affecting vision and requiring careful and prolonged management. Eyelid involvement in AKC can lead to chronic blepharitis, madarosis, and eyelid scarring, which may pose challenges for contact lens wear and impact cosmesis.

Managing allergic conjunctivitis, particularly severe forms, can also impose other burdens on patients. Frequent visits to eye specialists for monitoring and treatment adjustments, and the ongoing need to purchase prescription eye drops and other medications, can result in increased healthcare costs and time off from work or school for appointments. Moreover, the use of medications to manage allergic symptoms, such as topical corticosteroids, may carry the risk of adverse reactions, including the development of cataracts and glaucoma with prolonged use, necessitating careful monitoring and management of medication-related side effects.

Review Questions

[Placeholder for Review Questions – Consider adding multiple-choice questions related to differential diagnosis, treatment, and management of allergic conjunctivitis subtypes.]

Figure: Allergic Conjunctivitis. Illustrative image showing the clinical presentation of allergic conjunctivitis in one eye, characterized by conjunctival redness, chemosis, and eyelid edema.

References

[Include the original references here, ensuring they are correctly formatted and numbered.]

1.La Rosa M, Lionetti E, Reibaldi M, Russo A, Longo A, Leonardi S, Tomarchio S, Avitabile T, Reibaldi A. Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr. 2013 Mar 14;39:18.
2.Labib BA, Chigbu DI. Therapeutic Targets in Allergic Conjunctivitis. Pharmaceuticals (Basel). 2022 Apr 28;15(5)
3.Villegas BV, Benitez-Del-Castillo JM. Current Knowledge in Allergic Conjunctivitis. Turk J Ophthalmol. 2021 Feb 25;51(1):45-54.
4.Katelaris CH. Ocular allergy in the Asia Pacific region. Asia Pac Allergy. 2011 Oct;1(3):108-14.
5.Moote W, Kim H, Ellis AK. Allergen-specific immunotherapy. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):53.
6.Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):51.
7.Doğan Ü, Ağca S. Investigation of possible risk factors in the development of seasonal allergic conjunctivitis. Int J Ophthalmol. 2018;11(9):1508-1513.
8.Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16:5.
9.Rathi VM, Murthy SI. Allergic conjunctivitis. Community Eye Health. 2017;30(99):S7-S10.
10.Leonardi A. Management of vernal keratoconjunctivitis. Ophthalmol Ther. 2013 Dec;2(2):73-88.
11.Gupta J, Johansson E, Bernstein JA, Chakraborty R, Khurana Hershey GK, Rothenberg ME, Mersha TB. Resolving the etiology of atopic disorders by using genetic analysis of racial ancestry. J Allergy Clin Immunol. 2016 Sep;138(3):676-699.
12.Katelaris CH. Giant papillary conjunctivitis–a review. Acta Ophthalmol Scand Suppl. 1999;(228):17-20.
13.Kaur K, Gurnani B. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 11, 2023. Vernal Keratoconjunctivitis.
14.Ojeda P, Sastre J, Olaguibel JM, Chivato T., investigators participating in the National Survey of the Spanish Society of Allergology and Clinical Immunology Alergológica 2015. Alergológica 2015: A National Survey on Allergic Diseases in the Adult Spanish Population. J Investig Allergol Clin Immunol. 2018 Jun;28(3):151-164.
15.Sen E, Celik S, Inanc M, Elgin U, Ozyurt B, Yılmazbas P. Seasonal distribution of ocular conditions treated at the emergency room: a 1-year prospective study. Arq Bras Oftalmol. 2018 Apr;81(2):116-119.
16.Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, Azar A, Baroody FM, Bachert C, Canonica GW, Chacko T, Cingi C, Ciprandi G, Corey J, Cox LS, Creticos PS, Custovic A, Damask C, DeConde A, DelGaudio JM, Ebert CS, Eloy JA, Flanagan CE, Fokkens WJ, Franzese C, Gosepath J, Halderman A, Hamilton RG, Hoffman HJ, Hohlfeld JM, Houser SM, Hwang PH, Incorvaia C, Jarvis D, Khalid AN, Kilpeläinen M, Kingdom TT, Krouse H, Larenas-Linnemann D, Laury AM, Lee SE, Levy JM, Luong AU, Marple BF, McCoul ED, McMains KC, Melén E, Mims JW, Moscato G, Mullol J, Nelson HS, Patadia M, Pawankar R, Pfaar O, Platt MP, Reisacher W, Rondón C, Rudmik L, Ryan M, Sastre J, Schlosser RJ, Settipane RA, Sharma HP, Sheikh A, Smith TL, Tantilipikorn P, Tversky JR, Veling MC, Wang Y, Westman M, Wickman M, Zacharek M. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018 Feb;8(2):108-352.
17.Kenny SE, Tye CB, Johnson DA, Kheirkhah A. Giant papillary conjunctivitis: A review. Ocul Surf. 2020 Jul;18(3):396-402.
18.Sacchetti M, Plateroti R, Bruscolini A, Giustolisi R, Marenco M. Understanding Vernal Keratoconjunctivitis: Beyond Allergic Mechanisms. Life (Basel). 2021 Sep 26;11(10)
19.Jordakieva G, Jensen-Jarolim E. The impact of allergen exposure and specific immunotherapy on circulating blood cells in allergic rhinitis. World Allergy Organ J. 2018;11(1):19.
20.Li A, Li S, Ruan F, Jie Y. Atopic keratoconjunctivitis: A diagnostic dilemma-a case report. Medicine (Baltimore). 2018 Apr;97(16):e0372.
21.Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S73-80.
22.Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008 Jul 24;454(7203):445-54.
23.Hashmi MF, Gurnani B, Benson S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 26, 2024. Conjunctivitis.
24.Baab S, Le PH, Gurnani B, Kinzer EE. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 26, 2024. Allergic Conjunctivitis.
25.Tuft SJ, Cree IA, Woods M, Yorston D. Limbal vernal keratoconjunctivitis in the tropics. Ophthalmology. 1998 Aug;105(8):1489-93.
26.Singh P, Gupta A, Tripathy K. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 25, 2023. Keratitis.
27.Jeng BH, Whitcher JP, Margolis TP. Pseudogerontoxon. Clin Exp Ophthalmol. 2004 Aug;32(4):433-4.
28.Azari AA, Arabi A. Conjunctivitis: A Systematic Review. J Ophthalmic Vis Res. 2020 Jul-Sep;15(3):372-395.
29.Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: A review. J Am Acad Dermatol. 2014 Mar;70(3):569-75.
30.Vaidyanathan U, Hopping GC, Liu HY, Somani AN, Ronquillo YC, Hoopes PC, Moshirfar M. Persistent Corneal Epithelial Defects: A Review Article. Med Hypothesis Discov Innov Ophthalmol. 2019 Fall;8(3):163-176.
31.Liu A, Manche EE. Bilateral posterior subcapsular cataracts associated with long-term intranasal steroid use. J Cataract Refract Surg. 2011 Aug;37(8):1555-8.
32.Wang T, Moinuddin O, Abuzaitoun R, Hwang M, Besirli C, Wubben TJ, Zacks DN. Retinal Detachment After Endophthalmitis: Risk Factors and Outcomes. Clin Ophthalmol. 2021;15:1529-1537.
33.Hanet MS, Zimpfer A, Lepper S, Seitz B. Keratoconus-like tomographic changes in a case of recurrent interstitial keratitis. J Ophthalmic Inflamm Infect. 2018 Mar 07;8(1):4.
34.Gurnani B, Kaur K. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 11, 2023. Contact Lenses.
35.Arasi S, Corsello G, Villani A, Pajno GB. The future outlook on allergen immunotherapy in children: 2018 and beyond. Ital J Pediatr. 2018 Jul 11;44(1):80.
36.Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol. 2008 Sep;153 Suppl 1(Suppl 1):17-21.
37.Carr W, Schaeffer J, Donnenfeld E. Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief. Allergy Rhinol (Providence). 2016 Jan;7(2):107-14.
38.Mehta R. Allergy and Asthma: Allergic Rhinitis and Allergic Conjunctivitis. FP Essent. 2018 Sep;472:11-15.
39.Takamura E. [GUIDELINES FOR THE CLINICAL MANAGEMENT OF ALLERGIC CONJUNCTIVAL DISEASE THE POINT OF THE MANAGEMENT WITH USING CONVENTIONAL TOOL AND EYE DROPS]. Arerugi. 2018;67(2):103-107.
40.Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, Halken S, Larenas-Linnemann D, Pawankar R, Pitsios C, Sheikh A, Worm M, Arasi S, Calderon MA, Cingi C, Dhami S, Fauquert JL, Hamelmann E, Hellings P, Jacobsen L, Knol EF, Lin SY, Maggina P, Mösges R, Oude Elberink JNG, Pajno GB, Pastorello EA, Penagos M, Rotiroti G, Schmidt-Weber CB, Timmermans F, Tsilochristou O, Varga EM, Wilkinson JN, Williams A, Zhang L, Agache I, Angier E, Fernandez-Rivas M, Jutel M, Lau S, van Ree R, Ryan D, Sturm GJ, Muraro A. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018 Apr;73(4):765-798.
41.Verin PH, Dicker ID, Mortemousque B. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. Clin Exp Allergy. 1999 Apr;29(4):529-36.
42.Ackerman S, Smith LM, Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Ther Adv Chronic Dis. 2016 Jan;7(1):52-67.
43.Putnam CM. Diagnosis and management of blepharitis: an optometrist’s perspective. Clin Optom (Auckl). 2016;8:71-78.
44.Minutello K, Gupta V. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 28, 2024. Cromolyn Sodium.
45.Gaynes BI, Onyekwuluje A. Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension. Clin Ophthalmol. 2008 Jun;2(2):355-68.
46.Karimian F, Faramarzi A, Fekri S, Mohammad-Rabie H, Najdi D, Doozandeh A, Delfaza-Baher S, Yaseri M. Comparison of Loteprednol with Fluorometholone after Myopic Photorefractive Keratectomy. J Ophthalmic Vis Res. 2017 Jan-Mar;12(1):11-16.
47.Al-Mujaini A, Al-Kharusi N, Thakral A, Wali UK. Bacterial keratitis: perspective on epidemiology, clinico-pathogenesis, diagnosis and treatment. Sultan Qaboos Univ Med J. 2009 Aug;9(2):184-95.
48.Banerjee S, McCormack S. Acetylcysteine for Patients Requiring Mucous Secretion Clearance: A Review of Clinical Effectiveness and Safety [Internet]. Canadian Agency for Drugs and Technologies in Health; Ottawa (ON): Jun 14, 2019.
49.Chatterjee A, Bandyopadhyay S, Kumar Bandyopadhyay S. Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children. J Ophthalmic Vis Res. 2019 Oct-Dec;14(4):412-418.
50.Hazarika AK, Singh PK. Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. J Nat Sci Biol Med. 2015 Aug;6(Suppl 1):S10-2.
51.Singh S, Pal V, Dhull CS. Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis. Indian J Ophthalmol. 2001 Dec;49(4):241-5.
52.Farzam K, Sabir S, O’Rourke MC. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 10, 2023. Antihistamines.
53.De Benedetti G, Vaiano AS. Oral azithromycin and oral doxycycline for the treatment of Meibomian gland dysfunction: A 9-month comparative case series. Indian J Ophthalmol. 2019 Apr;67(4):464-471.
54.Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, Gridelli B, Boillot O, Manzanares J, Reding R. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet. 2004 Sep 18-24;364(9439):1054-61.
55.Lim L, Lim EWL. Therapeutic Contact Lenses in the Treatment of Corneal and Ocular Surface Diseases-A Review. Asia Pac J Ophthalmol (Phila). 2020 Dec;9(6):524-532.
56.Alipour F, Khaheshi S, Soleimanzadeh M, Heidarzadeh S, Heydarzadeh S. Contact Lens-related Complications: A Review. J Ophthalmic Vis Res. 2017 Apr-Jun;12(2):193-204.
57.Fung AT, Tran T, Lim LL, Samarawickrama C, Arnold J, Gillies M, Catt C, Mitchell L, Symons A, Buttery R, Cottee L, Tumuluri K, Beaumont P. Local delivery of corticosteroids in clinical ophthalmology: A review. Clin Exp Ophthalmol. 2020 Apr;48(3):366-401.
58.Bonini S, Sacchetti M, Mantelli F, Lambiase A. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):436-41.
59.Gokhale NS. Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm. Indian J Ophthalmol. 2016 Feb;64(2):145-8.
60.Krysik K, Dobrowolski D, Wylegala E, Lyssek-Boron A. Amniotic Membrane as a Main Component in Treatments Supporting Healing and Patch Grafts in Corneal Melting and Perforations. J Ophthalmol. 2020;2020:4238919.
61.Safadi K, Kruger JM, Chowers I, Solomon A, Amer R, Aweidah H, Frenkel S, Mechoulam H, Anteby I, Ben Eli H, Lavy I, Jaouni T, Landau D, Tiosano L, Greifner G, Ofir S, Levi Vineberg T, Levy J. Ophthalmology practice during the COVID-19 pandemic. BMJ Open Ophthalmol. 2020;5(1):e000487.
62.Ciprandi G, Licari A, Marseglia GL. To prevent the allergic disease: the dream of the allergist. Acta Biomed. 2020 Aug 27;91(3):e2020073.
63.Sacchetti M, Abicca I, Bruscolini A, Cavaliere C, Nebbioso M, Lambiase A. Allergic conjunctivitis: current concepts on pathogenesis and management. J Biol Regul Homeost Agents. 2018 Jan-Feb;32(1 Suppl. 1):49-60.
64.Shaker M, Salcone E. An update on ocular allergy. Curr Opin Allergy Clin Immunol. 2016 Oct;16(5):505-10.
65.Sgrulletta R, Bonini S, Lambiase A, Bonini S. Allergy and infections: long-term improvement of vernal keratoconjunctivitis following viral conjunctivitis. Eur J Ophthalmol. 2006 May-Jun;16(3):470-3.
66.Passali D, Cingi C, Staffa P, Passali F, Muluk NB, Bellussi ML. The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018 Jan;8(1):e7.
67.Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, Agarwal A, Netuveli G, Roberts G, Pfaar O, Muraro A, Ansotegui IJ, Calderon M, Cingi C, Durham S, van Wijk RG, Halken S, Hamelmann E, Hellings P, Jacobsen L, Knol E, Larenas-Linnemann D, Lin S, Maggina P, Mösges R, Oude Elberink H, Pajno G, Panwankar R, Pastorello E, Penagos M, Pitsios C, Rotiroti G, Timmermans F, Tsilochristou O, Varga EM, Schmidt-Weber C, Wilkinson J, Williams A, Worm M, Zhang L, Sheikh A. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017 Nov;72(11):1597-1631.

Disclosures:

[Include the original disclosures here.]

Disclosure: Shad Baab declares no relevant financial relationships with ineligible companies.

Disclosure: Patrick Le declares no relevant financial relationships with ineligible companies.

Disclosure: Bharat Gurnani declares no relevant financial relationships with ineligible companies.

Disclosure: Eilene Kinzer declares no relevant financial relationships with ineligible companies.